Carmela Ciardullo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carmela Ciardullo has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Christos Vaklavas
Huntsman Cancer Institute, University of Utah
16 shared publications - Irene Moreno
START Madrid- CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain
16 shared publications - Ivan Victoria
Medical Oncology Department, Hospital Clinic i Provincial de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain
16 shared publications - Justin P. O. Lindemann
Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
16 shared publications - Mafalda Oliveira
Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron Hospital, Barcelona, Spain
16 shared publications - Richard D. Baird
Department of Oncology, University of Cambridge, Cambridge, UK
16 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 4 shows the longitudinal ctDNA dynamics of all patients on study.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 4 shows the longitudinal ctDNA dynamics of all patients on study.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 1 shows genome-wide patterns of somatic copy number variation based on baseline plasma ctDNA from n = 27 patients.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 1 shows genome-wide patterns of somatic copy number variation based on baseline plasma ctDNA from n = 27 patients.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Table 1 shows PIK3CA and PTEN alterations in baseline ctDNA samples, with associated mutation type, amino acid change, allele frequency, OncoKB classification, SIFT/PolyPhen predictions, and affected protein domain.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Table 1 shows PIK3CA and PTEN alterations in baseline ctDNA samples, with associated mutation type, amino acid change, allele frequency, OncoKB classification, SIFT/PolyPhen predictions, and affected protein domain.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 6 shows the clonal hematopoiesis mutation profiles and their influence on molecular response.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 6 shows the clonal hematopoiesis mutation profiles and their influence on molecular response.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 3 shows the relationship of baseline cfDNA levels and maximum and mean VAF to sum of target lesions, ECOG performance status, presence of liver or lung metastases, and treatment duration.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 3 shows the relationship of baseline cfDNA levels and maximum and mean VAF to sum of target lesions, ECOG performance status, presence of liver or lung metastases, and treatment duration.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Purpose:Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis despite initial treatment responses. This study evaluates ctDNA for monitoring disease and assessing the efficacy of first-line therapy in patients with extensive-stage SCLC (1L ES-SCLC).Experimental Design:In the TAZMAN trial, 31 patients with 1L ES-SCLC received standard treatment with durvalumab and etoposide plus carboplatin or cisplatin. We analyzed 228 plasma samples from 27 of 31 patients using a liquid biopsy approach to detect somatic mutations and copy-number aberrations, while also accounting for clonal hematopoiesis mutations.Results:Baseline ctDNA analysis detected somatic alterations in 96.3% of patients, primarily in genes like TP53 and RB1. ctDNA dynamics during early treatment showed significant reductions in variant allele frequency, confirming early but short-lived chemosensitivity. Reduction of ctDNA below the limit of detection of the assay during induction predicted patients with longer treatment duration, surpassing imaging in distinguishing these patients. ctDNA changes often anticipated disease relapse before conventional imaging, suggesting ctDNA as a more sensitive treatment efficacy marker.Conclusions:The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Purpose:Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis despite initial treatment responses. This study evaluates ctDNA for monitoring disease and assessing the efficacy of first-line therapy in patients with extensive-stage SCLC (1L ES-SCLC).Experimental Design:In the TAZMAN trial, 31 patients with 1L ES-SCLC received standard treatment with durvalumab and etoposide plus carboplatin or cisplatin. We analyzed 228 plasma samples from 27 of 31 patients using a liquid biopsy approach to detect somatic mutations and copy-number aberrations, while also accounting for clonal hematopoiesis mutations.Results:Baseline ctDNA analysis detected somatic alterations in 96.3% of patients, primarily in genes like TP53 and RB1. ctDNA dynamics during early treatment showed significant reductions in variant allele frequency, confirming early but short-lived chemosensitivity. Reduction of ctDNA below the limit of detection of the assay during induction predicted patients with longer treatment duration, surpassing imaging in distinguishing these patients. ctDNA changes often anticipated disease relapse before conventional imaging, suggesting ctDNA as a more sensitive treatment efficacy marker.Conclusions:The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 7 shows RECIST and ctDNA longitudinal assessment in the patient showing evidence of a newly acquired NOTCH3 variant on treatment.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 7 shows RECIST and ctDNA longitudinal assessment in the patient showing evidence of a newly acquired NOTCH3 variant on treatment.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 2 shows a density histogram of n = 27 baseline plasma ctDNA samples with copy number (log2 ratio) indicated on the x-axis and counts/density on the y-axis.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 2 shows a density histogram of n = 27 baseline plasma ctDNA samples with copy number (log2 ratio) indicated on the x-axis and counts/density on the y-axis.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 5 shows the RECIST and ctDNA longitudinal assessment in four representative patients.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 5 shows the RECIST and ctDNA longitudinal assessment in four representative patients.